Atlas Arteria Limited Logo

Atlas Arteria Limited

ALX.AX

(3.0)
Stock Price

4,92 AUD

2.97% ROA

3.79% ROE

29.54x PER

Market Cap.

6.913.204.950,00 AUD

27.23% DER

12.59% Yield

167.02% NPM

Atlas Arteria Limited Stock Analysis

Atlas Arteria Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Atlas Arteria Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.86x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (27%), which means it has a small amount of debt compared to the ownership it holds

3 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

4 ROE

The stock's ROE falls within an average range (5.35%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (4.35%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

7 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

8 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

9 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

10 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (3), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Atlas Arteria Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Atlas Arteria Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Atlas Arteria Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Atlas Arteria Limited Revenue
Year Revenue Growth
2010 94.724.000
2011 87.460.000 -8.31%
2012 89.595.000 2.38%
2013 890.000 -9966.85%
2014 1.466.000 39.29%
2015 2.212.000 33.73%
2016 2.694.000 17.89%
2017 83.225.000 96.76%
2018 132.377.999 37.13%
2019 166.925.000 20.7%
2019 167.763.000 0.5%
2020 104.556.000 -60.45%
2021 100.515.000 -4.02%
2022 118.241.000 14.99%
2023 134.000.000 11.76%
2024 278.400.000 51.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Atlas Arteria Limited Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Atlas Arteria Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 33.803.000
2011 36.208.000 6.64%
2012 36.065.000 -0.4%
2013 736.000 -4800.14%
2014 797.000 7.65%
2015 29.337.000 97.28%
2016 101.403.000 71.07%
2017 48.405.000 -109.49%
2018 119.304.000 59.43%
2019 0 0%
2019 33.891.000 100%
2020 7.512.000 -351.16%
2021 4.748.000 -58.21%
2022 9.773.000 51.42%
2023 33.200.000 70.56%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Atlas Arteria Limited EBITDA
Year EBITDA Growth
2010 -121.670.000
2011 -107.185.000 -13.51%
2012 -9.151.000 -1071.29%
2013 -23.529.000 61.11%
2014 -82.389.000 71.44%
2015 113.317.000 172.71%
2016 397.664.000 71.5%
2017 15.596.000 -2449.78%
2018 -24.340.000 164.08%
2019 163.568.000 114.88%
2019 67.688.000 -141.65%
2020 36.746.000 -84.21%
2021 36.565.000 -0.5%
2022 42.897.000 14.76%
2023 64.099.999 33.08%
2024 128.400.000 50.08%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Atlas Arteria Limited Gross Profit
Year Gross Profit Growth
2010 94.724.000
2011 87.460.000 -8.31%
2012 84.418.000 -3.6%
2013 890.000 -9385.17%
2014 1.466.000 39.29%
2015 1.283.000 -14.26%
2016 -62.485.000 102.05%
2017 67.978.000 191.92%
2018 100.252.000 32.19%
2019 125.141.000 19.89%
2019 39.139.000 -219.73%
2020 -13.547.000 388.91%
2021 -9.048.000 -49.72%
2022 116.000 7900%
2023 16.400.000 99.29%
2024 33.600.000 51.19%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Atlas Arteria Limited Net Profit
Year Net Profit Growth
2010 -142.488.000
2011 -289.489.000 50.78%
2012 -124.435.000 -132.64%
2013 1.423.469.000 108.74%
2014 -50.561.000 2915.35%
2015 85.082.000 159.43%
2016 225.109.000 62.2%
2017 519.583.000 56.68%
2018 59.852.000 -768.11%
2019 -9.821.000 709.43%
2019 -9.821.000 0%
2020 -99.210.000 90.1%
2021 163.697.000 160.61%
2022 266.959.000 38.68%
2023 256.300.000 -4.16%
2024 456.800.000 43.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Atlas Arteria Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 0
2011 0 0%
2012 0 0%
2013 3 100%
2014 0 0%
2015 0 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Atlas Arteria Limited Free Cashflow
Year Free Cashflow Growth
2010 65.803.000
2011 43.037.000 -52.9%
2012 40.925.000 -5.16%
2013 10.166.000 -302.57%
2014 -24.554.000 141.4%
2015 -41.723.000 41.15%
2016 -15.576.000 -167.87%
2017 17.843.000 187.29%
2018 22.038.000 19.04%
2019 298.876.000 92.63%
2019 -3.938.000 7689.54%
2020 24.000.000 116.41%
2021 38.565.000 37.77%
2022 473.142.000 91.85%
2023 712.800.000 33.62%
2024 308.300.000 -131.2%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Atlas Arteria Limited Operating Cashflow
Year Operating Cashflow Growth
2010 66.952.000
2011 44.917.000 -49.06%
2012 45.255.000 0.75%
2013 10.904.000 -315.03%
2014 -24.554.000 144.41%
2015 -41.723.000 41.15%
2016 -15.576.000 -167.87%
2017 18.120.000 185.96%
2018 23.140.000 21.69%
2019 314.628.000 92.65%
2019 0 0%
2020 25.438.000 100%
2021 40.031.000 36.45%
2022 473.499.000 91.55%
2023 713.600.000 33.65%
2024 308.800.000 -131.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Atlas Arteria Limited Capital Expenditure
Year Capital Expenditure Growth
2010 1.149.000
2011 1.880.000 38.88%
2012 4.330.000 56.58%
2013 738.000 -486.72%
2014 0 0%
2015 0 0%
2016 0 0%
2017 277.000 100%
2018 1.102.000 74.86%
2019 15.752.000 93%
2019 3.938.000 -300%
2020 1.438.000 -173.85%
2021 1.466.000 1.91%
2022 357.000 -310.64%
2023 800.000 55.38%
2024 500.000 -60%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Atlas Arteria Limited Equity
Year Equity Growth
2010 -225.292.000
2011 -821.318.000 72.57%
2012 -980.586.000 16.24%
2013 875.560.000 212%
2014 822.893.000 -6.4%
2015 864.958.000 4.86%
2016 1.072.998.000 19.39%
2017 2.162.075.000 50.37%
2018 2.328.506.000 7.15%
2019 3.343.595.000 30.36%
2020 3.634.336.000 8%
2021 3.497.994.000 -3.9%
2022 6.490.472.000 46.11%
2023 9.100.800.000 28.68%
2024 6.113.500.000 -48.86%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Atlas Arteria Limited Assets
Year Assets Growth
2010 1.851.968.000
2011 1.629.909.000 -13.62%
2012 1.582.681.000 -2.98%
2013 882.314.000 -79.38%
2014 868.228.000 -1.62%
2015 893.324.000 2.81%
2016 1.176.868.000 24.09%
2017 4.010.127.000 70.65%
2018 4.628.532.000 13.36%
2019 5.675.493.000 18.45%
2020 5.268.921.000 -7.72%
2021 5.219.183.000 -0.95%
2022 8.332.834.000 37.37%
2023 8.059.400.000 -3.39%
2024 7.894.600.000 -2.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Atlas Arteria Limited Liabilities
Year Liabilities Growth
2010 2.077.260.000
2011 2.451.227.000 15.26%
2012 2.563.267.000 4.37%
2013 6.754.000 -37851.84%
2014 45.335.000 85.1%
2015 28.366.000 -59.82%
2016 103.870.000 72.69%
2017 1.848.052.000 94.38%
2018 2.300.026.000 19.65%
2019 2.331.898.000 1.37%
2020 1.634.585.000 -42.66%
2021 1.721.189.000 5.03%
2022 1.842.362.000 6.58%
2023 1.823.800.000 -1.02%
2024 1.781.100.000 -2.4%

Atlas Arteria Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.1
Net Income per Share
0.16
Price to Earning Ratio
29.54x
Price To Sales Ratio
49.34x
POCF Ratio
9.4
PFCF Ratio
9.41
Price to Book Ratio
1.13
EV to Sales
59.59
EV Over EBITDA
133.15
EV to Operating CashFlow
11.35
EV to FreeCashFlow
11.36
Earnings Yield
0.03
FreeCashFlow Yield
0.11
Market Cap
6,91 Bil.
Enterprise Value
8,35 Bil.
Graham Number
3.91
Graham NetNet
-1.07

Income Statement Metrics

Net Income per Share
0.16
Income Quality
3.14
ROE
0.04
Return On Assets
0.03
Return On Capital Employed
-0
Net Income per EBT
-3.44
EBT Per Ebit
8.3
Ebit per Revenue
-0.06
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.12
Operating Profit Margin
-0.06
Pretax Profit Margin
-0.49
Net Profit Margin
1.67

Dividends

Dividend Yield
0.13
Dividend Yield %
12.59
Payout Ratio
2.48
Dividend Per Share
0.6

Operating Metrics

Operating Cashflow per Share
0.51
Free CashFlow per Share
0.51
Capex to Operating CashFlow
0
Capex to Revenue
0.01
Capex to Depreciation
0.01
Return on Invested Capital
-0
Return on Tangible Assets
0.03
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,16
Book Value per Share
4,21
Tangible Book Value per Share
4.2
Shareholders Equity per Share
4.21
Interest Debt per Share
1.22
Debt to Equity
0.27
Debt to Assets
0.21
Net Debt to EBITDA
22.89
Current Ratio
2.26
Tangible Asset Value
6,10 Bil.
Net Current Asset Value
-1,51 Bil.
Invested Capital
180700000
Working Capital
0,15 Bil.
Intangibles to Total Assets
0
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Atlas Arteria Limited Dividends
Year Dividends Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Atlas Arteria Limited Profile

About Atlas Arteria Limited

Atlas Arteria Limited owns, develops, and operates toll roads. It holds a 13.4% interest in 22-kilometer toll road investors partnership II (TRIP II), the concessionaire for Dulles Greenway toll road located in Virginia, the United States. The company was formerly known as Macquarie Atlas Roads Limited and changed its name to Atlas Arteria Limited in May 2018. Atlas Arteria Limited was incorporated in 2009 and is based in Melbourne, Australia.

CEO
Mr. Graeme Francis Bevans
Employee
0
Address
180 Flinders Street
Melbourne, 3000

Atlas Arteria Limited Executives & BODs

Atlas Arteria Limited Executives & BODs
# Name Age
1 Mr. Vincent Portal-Barrault
Chief Operating Officer
70
2 Mr. David Collins
Chief Financial Officer
70
3 Mr. Hugh Wehby BEc (Hons), DipInvRel
Chief Executive Officer & MD
70
4 Tess Palmer
Director of Investor Relations
70
5 Mr. Graeme Francis Bevans
MD, Chief Executive Officer & Executive Director
70
6 Mr. Paul Lynch B.Com., L.L.B.
Joint Company Secretary
70
7 Navleen Prasad
Public Affairs Manager
70
8 Ms. Catherine Brain
Group Executive of People & Culture
70
9 Mr. Clayton John McCormack B.Com., L.L.B.
Company Secretary & General Counsel
70
10 Jim Dickson
Corporate Development & Strategy Executive
70

Atlas Arteria Limited Competitors